Back to search

Article

Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practice

2023-05-09

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold> The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS. <bold>Material and methods</bold> A multicen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
59bf3b1d-2c1e-5a3d-b9ba-43ba1d92cbc6
DOI
10.21203/rs.3.rs-2887055/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practiceDOI 10.21203/rs.3.rs-2887055/v1
Select a neighboring publication to make it the new centre.